

Receipt date: 04/11/2008

Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-08)

Approved for use through 03/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10751292
Filing Date	2004-01-02
First Named Inventor	Mark Hoffman
Art Unit	1631
Examiner Name	Karlheinz R. Skowronek
Attorney Docket Number	CRNI.107055

U.S.PATENTS**Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5758095		1998-05-26	Albaum, et al.	
	2	5833599		1998-11-10	Schrier, et al.	
	3	5989844		1999-11-23	Shimada, et al.	
	4	6067524		2000-05-23	Byerly, et al.	
	5	6081786		2000-06-27	Barry, et al.	
	6	6315720		2001-11-13	Williams, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add**U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KRS/

Receipt date: 04/11/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10751292
Filing Date	2004-01-02
First Named Inventor	Mark Hoffman
Art Unit	1631
Examiner Name	Karlheinz R. Skowronek
Attorney Docket Number	CRNI.107055

1	20020012921		2002-01-31	Stanton, Jr.	
2	20020038227		2002-03-28	Fey, et al.	
3	20020049772		2002-04-25	Rienhoff, Jr., et al.	
4	20020110823		2002-08-15	Hogan	

If you wish to add additional U.S. Published Application citation information please click the Add button. **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1211627	EP	A1	2002-05-06	Gut		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Evans, William E., et al., "Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics," Science Magazine, Vol. 286, No. 5439, October 15, 1999, pp. 487-491.	<input type="checkbox"/>
	2	Foubister, Yida, et al., "Expanded Genetic Testing Carries New Legal Risks," American Medical News, October 16, 1	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KRS/

Receipt date: 04/11/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10751292
Filing Date	2004-01-02
First Named Inventor	Mark Hoffman
Art Unit	1631
Examiner Name	Karlheinz R. Skowronek
Attorney Docket Number	CRNI.107055

3	ICHIKAWA, Y. Single nucleotide polymorphism to disclose severe side-effects or proper dosage for each patient. Internal Medicine. July, 2000. volume 39, no. 7, pages 523-524.	<input type="checkbox"/>
4	Lazarou, Jason, et al., "Incidence of Adverse Drug Reactions in Hospital Patients," JAMA, April 15, 1998, Vol. 279, No. 15.	<input type="checkbox"/>
5	Meyer, Un A.. et al., "Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism," Annu. Rev. Pharmacol., Toxicol. 1997, 37:269-96.	<input type="checkbox"/>
6	Sundberg, Magnus. Ingelman- et al., "Polymorphic Human Cytochrome P450 Enzyes: An Opportunity for Individualized Drug Treatment . . . ", J. Clin Pharmacol. 2000; 40:930-938.	<input type="checkbox"/>
7	Usami et al. J. Human Genetics (1999) vol. 4415, pp. 304-307	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Karlheinz Skowronek/ (07/15/2008)	Date Considered	07/15/2008
--------------------	------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.